Crabtree B, Zajarías A, Portal C, Téllez N, Halabe J

Language: Spanish
References: 13
Page: 77-80
PDF size: 779.18 Kb.

Text Extraction

No Abstract

REFERENCES

1. Ammash NM, Seward JB, Bailey KR. Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation 2000:2490-2496.

2. Zieman SJ, Fortuin NJ. Hypertrophic and restrictive cardiomyopathies. Cardiol Clin 1999;17:159-170.

3. Vaitkus PT, Kussmaul WG. Constrictive pericarditis versus restrictive cardiomyopathy: a repraisal ando update of diagnostic criteria. Am Heart J 1991;122:1431-1441.

4. Kabbani SS, LeWinter MM. Diastolic heart failure. Constrictive, restrictive and pericardial. Cardiol Clin 2000;18(3):501-509.

5. Kushawa S, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med 1997;336:267-276.

6. Falk RH, Comenzo RL, Skinner M. The systemic amyloidosis. N Engl J Med 1997;337:898-909.

7. Duberey SW, Mendes L, Skinner M. Resolution of the heart failure in patients with AL amyloidosis. Blood 1991;77:257-262.

8. Duberey SW, Cha K. Familial and primary (AL) cardiac amyloidosis: Echocardiographically similar diseases with different clinical outcomes. Heart 1997:78:74-82.

9. Kyle Ra, Gertz MA, Griepp PR. A trail of three regimens for primary amyloidosis: colchicines alone, melphalan and prednisone, prednisone and colchicines. N Engl J Med 1997;336:1202-1207.

10. Comenzo RL. Hematopoyetic cell transplantation for primary systemic amyloidosis: what have we learned. Leuk lynphoma 2000;37:245-248.

11. Comenzo RL, Vosburgh E, Falk. Does intensive melphalan with blood stemcell support for treatment of AL amyloidosis: survival and responses in 25 patients. Blood 1998;9:3662-3670.

12. Gerts MA, Lacy MQ, Gastineau DA. Blood stem-cell transplantation as a therapy for primary systemic amyloidosis. Bone Marrow Transplant 2000;26:963-969.

13. Rives S, Martinez C, Carreras E. High dose melphalan treatment followed by hematopoietic progenitor cell rescue in primary amyloidosis. Med Clin 2000;115:216-220.